98 related articles for article (PubMed ID: 230791)
1. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides.
Prigent AF; Nemoz G; Roche M; Pacheco H
Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791
[TBL] [Abstract][Full Text] [Related]
2. A polypeptide (AP-A) from sea anemone (Anthopleura xanthogrammica) with potent positive inotropic action.
Shibata S; Norton TR; Izumi T; Matsuo T; Katsuki S
J Pharmacol Exp Ther; 1976 Nov; 199(2):298-309. PubMed ID: 10426
[TBL] [Abstract][Full Text] [Related]
3. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
4. Effect of milrinone on ethanol and halothane induced cardiodepression.
Neira S; Penna M
Acta Physiol Pharmacol Latinoam; 1988; 38(2):193-211. PubMed ID: 2847492
[TBL] [Abstract][Full Text] [Related]
5. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.
Endoh M; Yanagisawa T; Morita T; Taira N
J Pharmacol Exp Ther; 1985 Jul; 234(1):267-73. PubMed ID: 2989507
[TBL] [Abstract][Full Text] [Related]
7. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
8. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
9. Frequency modulation of the inotropic action of isoproterenol in mouse heart.
Barovsky K; Gross SR
J Pharmacol Exp Ther; 1981 May; 217(2):314-25. PubMed ID: 6262482
[TBL] [Abstract][Full Text] [Related]
10. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.
Endoh M; Yamashita S; Taira N
J Pharmacol Exp Ther; 1982 Jun; 221(3):775-83. PubMed ID: 6283063
[TBL] [Abstract][Full Text] [Related]
11. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
12. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
Mushlin P; Boerth RC; Wells JN
Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
[No Abstract] [Full Text] [Related]
13. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.
Ogawa T; Ohhara H; Tsunoda H; Kuroki J; Shoji T
Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of inotropic action of xestoquinone, a novel cardiotonic agent isolated from a sea sponge.
Kobayashi M; Nakamura H; Kobayashi J; Ohizumi Y
J Pharmacol Exp Ther; 1991 Apr; 257(1):82-9. PubMed ID: 1850480
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
Follath F; Kersting F; Lewis GR; Dollery CT
Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
[No Abstract] [Full Text] [Related]
16. Myocardial effects of flavonoids from Crataegus species.
Schüssler M; Hölzl J; Fricke U
Arzneimittelforschung; 1995 Aug; 45(8):842-5. PubMed ID: 7575743
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
Nagata K; Ogawa T; Omosu M; Fujimoto K; Hayashi S
Arzneimittelforschung; 1985; 35(7):1034-6. PubMed ID: 2996562
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of cyclic AMP and contractile responses to isoprenaline: effects of a dihydropyridine derivative, nicardipine (YC-93), on canine ventricular muscle.
Endoh M; Yanagisawa T; Taira N
Eur J Pharmacol; 1980 Oct; 67(2-3):225-33. PubMed ID: 6257529
[TBL] [Abstract][Full Text] [Related]
19. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.
Armah BI; Muster D; Raap A; Brückner R; Graziadei I
Arzneimittelforschung; 1989 Nov; 39(11):1384-92. PubMed ID: 2559738
[TBL] [Abstract][Full Text] [Related]
20. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
